Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) COO Sells 5,209 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) COO Daniel Lesueur sold 5,209 shares of the company's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $4.15, for a total transaction of $21,617.35. Following the transaction, the chief operating officer now directly owns 211,041 shares of the company's stock, valued at $875,820.15. This trade represents a 2.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Daniel Lesueur also recently made the following trade(s):

• On Wednesday, March 5th, Daniel Lesueur sold 16,902 shares of Health Catalyst stock. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04.
• On Wednesday, February 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $5.76, for a total value of $30,003.84.

Health Catalyst Stock Up 2.6 %

Health Catalyst stock traded up $0.10 during midday trading on Friday, hitting $3.93. 437,085 shares of the stock were exchanged, compared to its average volume of 616,952. Health Catalyst, Inc. has a 1 year low of $3.60 and a 1 year high of $9.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The firm has a market cap of $275.93 million, a P/E ratio of -2.91 and a beta of 1.43. The company has a 50 day moving average price of $4.65 and a two-hundred day moving average price of $6.50.

Institutional Trading of Health Catalyst

A number of hedge funds and other institutional investors have recently modified their holdings of HCAT. Group One Trading LLC lifted its stake in shares of Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company's stock worth $31,000 after acquiring an additional 2,260 shares in the last quarter. Two Sigma Securities LLC increased its holdings in Health Catalyst by 19.5% during the 4th quarter. Two Sigma Securities LLC now owns 17,510 shares of the company's stock worth $124,000 after purchasing an additional 2,862 shares during the last quarter. Legato Capital Management LLC raised its position in shares of Health Catalyst by 3.7% in the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company's stock valued at $622,000 after purchasing an additional 3,171 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Health Catalyst in the 4th quarter valued at approximately $29,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Health Catalyst by 8.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company's stock valued at $442,000 after buying an additional 4,798 shares during the last quarter. 85.00% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on HCAT shares. Wells Fargo & Company cut their price objective on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a report on Tuesday, January 21st. Stifel Nicolaus reduced their price target on shares of Health Catalyst from $10.00 to $5.00 and set a "hold" rating on the stock in a research report on Thursday, February 27th. KeyCorp upgraded shares of Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a research note on Wednesday, January 8th. Royal Bank of Canada cut their target price on shares of Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 27th. Finally, Citigroup reduced their target price on shares of Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $8.73.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.